Prilenia Appoints Rob Lauzen as Chief Financial Officer and Jason Marks as Chief Legal Officer
Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share (AMRN)
Last amarin corporation plc - american depositary shares, each representing one ordinary share earnings: 4/30 05:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.amarincorp.com/investors
Company Research
Source: Business Wire
Expanded leadership team positioned to advance the company’s development and commercialization plans NAARDEN, The Netherlands & WALTHAM, Mass.--(BUSINESS WIRE)--Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, today announced the appointment of two key leaders to its management team – Mr. Rob Lauzen as Chief Financial Officer (CFO) and Mr. Jason Marks, J.D. as Chief Legal Officer (CLO). The appointments are aligned with Prilenia’s progress toward the potential commercialization of pridopidine.This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240919664330/en/Rob Lauzen, Chief Financial Officer, Prilenia (Photo: Business Wire)“This is a transformational time for Prilenia,” said Dr. Michael R. Hayden, CEO of Prilenia. “Rob and Jason bring outstanding expertise to
Show less
Read more
Impact Snapshot
Event Time:
AMRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMRN alerts
High impacting Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share news events
Weekly update
A roundup of the hottest topics
AMRN
News
- Amarin Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
- Amarin Announces Two Upcoming Investor EventsGlobeNewswire
- Affinia Therapeutics Announces the Appointment of Rami Daoud as Chief Business and Financial OfficerPR Newswire
- Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual EuropeGlobeNewswire
- Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) CongressGlobeNewswire
AMRN
Earnings
- 10/30/24 - Beat
AMRN
Sec Filings
- 10/31/24 - Form 3
- 10/30/24 - Form 10-Q
- 10/30/24 - Form 8-K
- AMRN's page on the SEC website